Therapy News and Research

RSS

Study demonstrates how CN2097 works to restore neural functions impaired by Angelman syndrome

In a new study in mice, a scientific collaboration centered at Brown University lays out in unprecedented detail a neurological signaling breakdown in Angelman syndrome, a disorder that affects thousands of children each year, characterized by developmental delay, seizures, and other problems.

14 Feb 2013

FDA allows Scioderm’s SD-101 IND application for Epidermolysis Bullosa to proceed

Scioderm announced that the US Food and Drug Administration (FDA) has reviewed and allowed the investigational new drug (IND) application for SD-101 to proceed. SD-101 is a topical treatment being developed for the treatment of Epidermolysis Bullosa (EB).

14 Feb 2013

Blood’s tendency to clot may contribute to white matter hyperintensities in post-menopausal women

New Mayo Clinic research suggests that blood may hold clues to whether post-menopausal women may be at an increased risk for areas of brain damage that can lead to memory problems and possibly increased risk of stroke. The study shows that blood's tendency to clot may contribute to areas of brain damage called white matter hyperintensities.

14 Feb 2013

Meridian receives ADA's Certificate of Education Recognition for diabetes education program

The American Diabetes Association (ADA) has awarded Meridian Medical Associates a Certificate of Education Recognition for its diabetes self-management education program.

13 Feb 2013

Ability to tune gene activity will permit refined research for drug resistance, cancer

Scientists who built a synthetic gene circuit that allowed for the precise tuning of a gene's expression in yeast have now refined this new research tool to work in human cells, according to research published online in Nature Communications.

13 Feb 2013

Tivozanib overall survival results announced by AVEO and Astellas

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) announced overall survival (OS) for tivozanib, an investigational agent, from the Phase 3 TIVO-1 (TIvozanib Versus sOrafenib in 1st line advanced RCC) study in patients with advanced renal cell carcinoma (RCC). The final OS analysis, as specified by the protocol, shows a median OS of 28.8 months (95% confidence interval [CI]: 22.5–NA) for tivozanib versus a median OS of 29.3 months (95% CI: 29.3–NA) for the comparator arm, sorafenib.

13 Feb 2013

Scopolamine may also be possible treatment for anxiety disorders

However, scopolamine is re-emerging as an antidepressant, with recent studies showing that scopolamine can rapidly improve mood in depressed patients. In addition, in a new study published in Biological Psychiatry this month by Dr. Moriel Zelikowsky and colleagues at the University of California, Los Angeles, it may also be a possible treatment for anxiety disorders.

13 Feb 2013

HRI to begin enrollment in RAD001 Phase II trial for Neurofibromatosis Type-2

House Research Institute (HRI) is recruiting patients for a Phase II clinical trial to test a medication that may slow the progression of Neurofibromatosis Type-2, commonly referred to as NF2.

13 Feb 2013

New drug delivery system can reduce size of ovarian tumors by as much as 83%

By loading fragile RNA into silicon nanoparticles, researchers from The Methodist Hospital and two other institutions found a new drug delivery system can reduce the size of ovarian tumors by as much as 83 percent -- and stop tumor growth in chemotherapy-resistant ovarian cancer tissue.

13 Feb 2013

New medication could help patients with renal tumours triggered by tuberous sclerosis

In collaboration with the Berlin TSC Centre, Charité - Universitätsmedizin Berlin has developed a new therapy for patients suffering from renal tumours associated with the rare genetic disease tuberous sclerosis (TSC).

13 Feb 2013

RNAi effective in treating cancer patients

The new study published in Cancer Discovery, the flagship journal of the American Association of Cancer Research (AACR), involving three Spanish and six American research centres, presents significant results in treating cancer patients with nanoparticles containing ribonucleic acid interference (RNAi) molecules.

13 Feb 2013

Boston College biologist receives $2.7M NIH grant to continue HIV and AIDS research

Boston College biologist Ken Williams, whose research focuses on the role of immunological cells in a range of illnesses that strike people living with HIV and AIDS, has been awarded a five-year, $2.7 million grant from the NIH's National Institute of Neurological Disorders and Stroke.

12 Feb 2013

LASAG trial for severe influenza initiated

...

12 Feb 2013

Intratympanic versus systemic steroid improves sudden hearing loss

Intratympanic treatment with the steroid dexamethasone should be considered as a salvage therapy for patients who have not responded to systemic treatment for sudden sensorineural hearing loss, suggest study findings.

12 Feb 2013

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Metastatic renal cell carcinoma is a devastating disease. There are roughly 20-25,000 new cases per year in the United States and it is increasing for some reason.

12 Feb 2013

Blood vessels play an important role in preventing spread of tumour cells

A lack of the protein endoglin in the blood vessels of tumour-bearing mice enables the spread of daughter tumours, according to researchers at Karolinska Institutet and Lund University in Sweden in a study published in the scientific periodical The Journal of Experimental Medicine. Given that the tumour vasculature constitutes an important barrier to the spread of cancer cells, the team suggests that drugs should be developed to strengthen the blood vessels' protective function.

12 Feb 2013

We Care Health Services acquires Pace Group of Companies

We Care Health Services (We Care), Canada's most trusted name in home health care and support services, is pleased to announce that it is further expanding its comprehensive health care portfolio with the acquisition of the Kitchener-Waterloo based Pace Group of Companies (Pace).

12 Feb 2013

New cancer research to be highlighted in AACR Annual Meeting 2013

The AACR Annual Meeting 2013 will bring more than 17,000 scientists, advocates, industry leaders and other professionals to Washington, D.C., for the latest in breakthrough cancer science.

12 Feb 2013

Enzyme therapy slows progression of Batten disease in dogs

Batten disease is a rare, fatal genetic disorder that affects children. Currently, no effective treatment exists for the disease, which ultimately kills all who are affected. Dachshunds also suffer from Batten disease, and now researchers from the University of Missouri College of Veterinary Medicine and School of Medicine, in collaboration with BioMarin Pharmaceutical Inc., have developed a treatment for the disease that has significantly delayed the onset and progression of symptoms in the Dachshunds.

12 Feb 2013

Skilled Healthcare fourth quarter revenue increases 2.4% to $219.2 million

Skilled Healthcare Group, Inc. today announced its consolidated financial operating results for the three and twelve-month period ended December 31, 2012.

12 Feb 2013

Therapy News and Research

Study demonstrates how CN2097 works to restore neural functions impaired by Angelman syndrome

FDA allows Scioderm’s SD-101 IND application for Epidermolysis Bullosa to proceed

Blood’s tendency to clot may contribute to white matter hyperintensities in post-menopausal women

Meridian receives ADA's Certificate of Education Recognition for diabetes education program

Ability to tune gene activity will permit refined research for drug resistance, cancer

Tivozanib overall survival results announced by AVEO and Astellas

Scopolamine may also be possible treatment for anxiety disorders

HRI to begin enrollment in RAD001 Phase II trial for Neurofibromatosis Type-2

New drug delivery system can reduce size of ovarian tumors by as much as 83%

New medication could help patients with renal tumours triggered by tuberous sclerosis

RNAi effective in treating cancer patients

Boston College biologist receives $2.7M NIH grant to continue HIV and AIDS research

LASAG trial for severe influenza initiated

Intratympanic versus systemic steroid improves sudden hearing loss

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Blood vessels play an important role in preventing spread of tumour cells

We Care Health Services acquires Pace Group of Companies

New cancer research to be highlighted in AACR Annual Meeting 2013

Enzyme therapy slows progression of Batten disease in dogs

Skilled Healthcare fourth quarter revenue increases 2.4% to $219.2 million

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News